Immunic stock: Q3 loss widens as ENSURE data stays on track
Published on 11/13/2026 at 22:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for Immunic investors
- Immunic reported a third-quarter net loss of USD 42.3 million and operating expenses of USD 43.4 million.
- Top-line data from the ENSURE-1 and ENSURE-2 Phase 3 trials remains expected in December 2026.
- The company said its USD 132.0 million cash balance should fund operations into late 2027.
Immunic reported a net loss of USD 42.3 million for the third quarter ended September 30, 2026, as the biotechnology company moved toward pivotal multiple sclerosis trial results expected in December. The company announced the figures on Friday, November 13, in a corporate update.
Immunic stock traded at 6.86 euros on Lang & Schwarz at 22:12 CET on Friday, November 13, 2026.
Higher spending ahead of trial data
Total operating expenses reached USD 43.4 million, including USD 13.9 million in non-cash charges, primarily related to stock compensation. Research and development expenses rose to USD 23.9 million from USD 20.0 million a year earlier, while general and administrative expenses increased to USD 19.4 million from USD 6.0 million.
The company attributed part of the higher general and administrative expense to a USD 11.0 million increase in personnel costs, including USD 9.7 million in non-cash stock compensation primarily related to a separation agreement. Cash and cash equivalents stood at USD 132.0 million at September 30, and Immunic said the balance should fund operations into late 2027.
ENSURE readout remains the next milestone
The fully enrolled ENSURE-1 and ENSURE-2 Phase 3 trials are evaluating vidofludimus calcium in relapsing multiple sclerosis. They randomized 1,121 and 1,100 patients, respectively, across more than 100 sites in 15 countries. Top-line data remains expected in December 2026.
Immunic said it is preparing for a potential U.S. New Drug Application in mid-2027 if the ENSURE results are positive. The company is also continuing initiation activities for the Phase 3 PROTECT-MS trial in progressive multiple sclerosis, with first-patient enrollment expected in the first half of 2027.
Immunic, Inc.
- Ticker: IMUX
- Exchange: Nasdaq
- Lang & Schwarz quote: 6.86 euros at 22:12 CET on November 13, 2026
- Third-quarter net loss: USD 42.3 million
- Cash and cash equivalents: USD 132.0 million at September 30, 2026
U.S. biotechnology shares traded against the backdrop of the Nasdaq Composite.
